With certain medications?

What are biosimilars, and how do they fit into the market of existing medications?

Biosimilars are high-quality, lower-cost alternatives to innovative biologic medications. They are created after the original biologic's patent has expired, allowing other companies to develop and market their own versions [1].

How are biosimilars regulated?

The U.S. FDA regulates biosimilars under the Biologics Price Competition and Innovation Act (BPCIA) of 2009. To bring a biosimilar to market, a company must demonstrate that their product is as safe and effective as the original biologic [2]. The FDA compares the biosimilar to the reference product through a comprehensive set of analytical and clinical studies.

Why are biosimilars important to patients?

Biosimilars are crucial for patients because they offer affordable alternatives to expensive biologic medications. By allowing multiple manufacturers to produce the same medication, competition is increased, and prices are driven down. According to the FDA, switching to a biosimilar can reduce a patient's medication costs by 15-50% [3].

What side effects are patients asking about?

Similar to original biologics, biosimilars can have similar side effects. However, biosimilars are not exact replicas of the original medication, and patients may experience new side effects. Patients should discuss their concerns and potential side effects with their healthcare provider [4].

Who makes biosimilars, and what are some notable examples?

Several companies develop biosimilars, including Sandoz, Mylan, and Pfizer. Notable examples of biosimilars include Zarxio (filgrastim-sndz), a biosimilar of Neupogen; and Erelzi (etanercept-szzs), a biosimilar of Enbrel.

When do patent exclusivities expire?

Patent exclusivities for original biologics, known as data exclusivity, expire 12 years after FDA approval. Biosimilar developers can then begin developing their versions of the medication. However, some exclusivities are extended through regulatory agreements or court decisions.

Sources

[1] DrugPatentWatch.com. Biosimilars: A Breakthrough for Patients.

[2] FDA.gov. Biosimilar Development and Review Process.

[3] FDA.gov. Biosimilars: What Patients Should Know.

[4] American Cancer Society. Biosimilars: What You Need to Know.